TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17534460

Group type: EXPERIMENTAL
Intervention: Dietary sodium intake of less than 100 mmol/day for prevention of hypertension; limited to 65 mmol/day to 100 mmol/day for hypertensive patients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 30 to 60 minutes, four to seven days per week.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure targets: lower than 140/90 mmHg for all patients; lower than 130/80 mmHg for those with diabetes or chronic kidney disease.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics as initial therapy for adults without compelling indications for other agents.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors, long-acting CCBs, ARBs, or beta-blockers as first-line therapy for diastolic and/or systolic hypertension.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors recommended for nondiabetic chronic kidney disease patients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin therapy for selected high-risk patients with hypertension.
Number of subjects: 0
Study: 15166932

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11588128

Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg daily)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 10051942

Group type: EXPERIMENTAL
Intervention: Midazolam-sufentanil (Group I)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sufentanil-enflurane (Group II)
Number of subjects: 32
Study: 7987837

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) at 1000 mg/m2 infused over 20 min
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cyclophosphamide (CP) at 1000 mg/m2 infused over 20 min with SR-2508 at 5 g/m2 infused over 20 min
Number of subjects: 6
Study: 2557307

Group type: EXPERIMENTAL
Intervention: Single daily fractions to the liver (3.0 Gy external beam radiation, total dose 21.0 Gy) with chemotherapy (Adriamycin 15 mg IV and 5-FU 500 mg IV, 2 hr before treatment on days 1, 3, 5, and 7)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Hyperfractionated whole liver external beam irradiation (1.2 Gy twice daily, 4 hr between treatments, 5 days per week to 24.0 Gy, 10 MV photons) with the same chemotherapy regimen
Number of subjects: 135
Study: 1149303

Group type: EXPERIMENTAL
Intervention: Apomorphine hydrochloride (0.75 mg s.c.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: L-DOPA (500 mg p.o.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Benztropine mesylate (1 mg i.m.)
Number of subjects: 9
Study: 31786655

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 15480

Group type: EXPERIMENTAL
Intervention: Supplementation with n-3 fatty acids
Number of subjects: 15480
Study: 31273298

Group type: EXPERIMENTAL
Intervention: Neurochemical biomarkers in spinal cord injury (SCI)
Number of subjects: 0
Study: 28618299

Group type: EXPERIMENTAL
Intervention: Internet guided self‐help cognitive‐behavioural treatment (ICBT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 120
Study: 26441220

Group type: EXPERIMENTAL
Intervention: Continuous micropump infusion of atropine and pralidoxime chloride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Repeated-bolus doses of atropine and pralidoxime chloride
Number of subjects: 60
Study: 23334108

Group type: EXPERIMENTAL
Intervention: Losses in various settings (Study 1-3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losses with no contrast effects (Study 4-5)
Number of subjects: 0
Study: 21676930

Group type: EXPERIMENTAL
Intervention: Crowded object recognition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crowding effect on object recognition
Number of subjects: 0
Study: 20209468

Group type: EXPERIMENTAL
Intervention: Pyruvate supplementation (2 g per day for 4 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pyruvate supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study: 17035735

Group type: EXPERIMENTAL
Intervention: HEXAVAC
Number of subjects: 7151

Group type: COMPARATOR
Intervention: PENTACOQ and HBVAXPRO
Number of subjects: 7151
Study: 15023205

Group type: EXPERIMENTAL
Intervention: Errata considered worthwhile obtaining (from information specialist's perspective)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Errata classified as likely to affect meta-analysis (from experienced reviewer/public health consultant's perspective)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Errata with significant errors affecting interpretation of RCT (from experienced reviewer/public health consultant's perspective)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Errata not considered important (from experienced reviewer/public health consultant's perspective)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Errata that matter in changing conclusions of systematic review
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall assessment of errata
Number of subjects: 100
Study: 10694117

Group type: EXPERIMENTAL
Intervention: Group D (2 h at 56% VO2max followed by eccentric contractions)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Group F (2 h at 56% VO2max with carbohydrate-electrolyte beverage followed by eccentric contractions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group C (10 sets of 10 eccentric contractions)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Group D
Number of subjects: 24
Study: 9234801

Group type: EXPERIMENTAL
Intervention: Strain chi4073 (delta cya delta crp delta cdt S. typhi Ty2) - 5 x 10(5) to 5 x 10(8) CFU
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Plasmid-containing derivatives of chi4073
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Strain chi4073
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chi4073 derivatives with Asd+ vector (with and without HBc-pre-S fusion)
Number of subjects: 40
Study: 8379835

Group type: EXPERIMENTAL
Intervention: 20pps electrical stimulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 45pps electrical stimulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80pps electrical stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (left limb)
Number of subjects: 30
Study: 3934915

Group type: EXPERIMENTAL
Intervention: s.c. salbutamol 0.5 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo 0.5 mg
Number of subjects: 14
Study: 31980132

Group type: EXPERIMENTAL
Intervention: MCT+
Number of subjects: 92

Group type: COMPARATOR
Intervention: CogPack
Number of subjects: 92
Study: 29500603

Group type: EXPERIMENTAL
Intervention: Nintedanib 50 mg orally after ketoconazole 400 mg once daily for 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg orally after rifampicin 600 mg once daily for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nintedanib alone (control for both studies)
Number of subjects: 60
Study: 27724833

Group type: EXPERIMENTAL
Intervention: Psychotherapy for TTM (details on dosage and duration not available)
Number of subjects: 245
Study: 24584708

Group type: EXPERIMENTAL
Intervention: ICG-assisted surgery
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BBG-assisted surgery
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TA-assisted surgery
Number of subjects: 48

Group type: COMPARATOR
Intervention: All groups (ICG, BBG, TA)
Number of subjects: 48
Study: 21535346

Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin FDC
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Metformin Monotherapy
Number of subjects: 1250
Study: 16091272

Group type: EXPERIMENTAL
Intervention: Subliminal words with pleasant and unpleasant meanings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal words analyzed at the subword level (bigrams and trigrams)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal priming
Number of subjects: 0
Study: 11786454

Group type: EXPERIMENTAL
Intervention: Information leaflet with standard verbal reassurance (Group A)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Standard verbal reassurance without information leaflet (Group A)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed (Group B)
Number of subjects: 259

Group type: COMPARATOR
Intervention: No antibiotics prescribed (Group A)
Number of subjects: 259
Study: 11477810

Group type: EXPERIMENTAL
Intervention: Zhiling Decoction (ZLD)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Naofukang
Number of subjects: 78
Study: 8597968

Group type: EXPERIMENTAL
Intervention: Ilioinguinal-iliohypogastric nerve block performed by anaesthetist using 0.25% plain bupivicaine (0.5 ml.kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ilioinguinal-iliohypogastric nerve block performed by surgeon using 0.25% plain bupivicaine (0.5 ml.kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children under two years of age
Number of subjects: 0
Study: 2527678

Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (three preprandial injections of short‐acting insulin (NovoPen) plus once daily extended‐acting insulin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (NovoPen)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Twice daily injections of short‐ and intermediate‐acting insulin
Number of subjects: 16
Study: 334436

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 100 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 200 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (various doses)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (higher doses)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 30419940

Group type: EXPERIMENTAL
Intervention: Training in communication skills using six strategies
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Training in communication skills
Number of subjects: 600
Study: 27814327

Group type: EXPERIMENTAL
Intervention: 1.5 mL of absolute alcohol (ethanol)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 1.5 mL of chlorpromazine (25 mg/mL)
Number of subjects: 32
Study: 23821131

Group type: EXPERIMENTAL
Intervention: Low-field intraoperative MRI guidance (iMRI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Frameless classic analogue STx biopsy (Control)
Number of subjects: 42
Study: 22703927

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 821
Study: 20808258

Group type: EXPERIMENTAL
Intervention: Quality improvement collaborative for diabetes management
Number of subjects: 1861

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1861
Study: 18277196

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) for 6 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no exercise training)
Number of subjects: 61
Study: 16880018

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire on hair removal practices and psychological impact
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Rosenberg Self-esteem Scale
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: WHOQOL-BREF
Number of subjects: 88
Study: 12925622

Group type: EXPERIMENTAL
Intervention: Achilles tendon lengthening
Number of subjects: 64

Group type: COMPARATOR
Intervention: Total-contact cast
Number of subjects: 64
Study: 10768588

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 578

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Fathers or other caretakers employed outside the home who spoke English
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Overall sociodemographic characteristics
Number of subjects: 578
Study: 8855675

Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg once daily
Number of subjects: 32
Study: 1510408

Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg, orally twice daily for 7 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Doxycycline (100 mg, orally twice daily for 7 days)
Number of subjects: 56
Study: 6392936

Group type: EXPERIMENTAL
Intervention: 80 mg nadolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 mg nadolol and 5 mg bendroflumethiazide
Number of subjects: 30
Study: 31655942

Group type: EXPERIMENTAL
Intervention: IONIS-APO(a)-LRX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Lp(a)-lowering approaches (niacin, PCSK9 inhibitors, mipomersen, lomitapide, lipoprotein apheresis)
Number of subjects: 0
Study: 30594232

Group type: EXPERIMENTAL
Intervention: Mobile phone application
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Breathalyzer
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 375
Study: 27175476

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PGJ) (250 g)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fermented sour sobya (FS) (170 g)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mixture of PGJ (150 g) and FS (140 g)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no supplements)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fresh apricot fruits (200 g)
Number of subjects: 35
Study: 25004347

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Thermal balloon ablation
Number of subjects: 81
Study: 22685234

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/d; n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 50
Study: 19765357

Group type: EXPERIMENTAL
Intervention: Neuropsychological (NP) test battery
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Hierarchical multiple regression analysis
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Ordinal logistic regression model
Number of subjects: 174
Study: 17850670

Group type: EXPERIMENTAL
Intervention: In-person discussion (Trial One)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No pre-test information (Trial One)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: In-person discussion (Trial Two)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Tablet PC-based video (Trial Two)
Number of subjects: 114
Study: 16208081

Group type: EXPERIMENTAL
Intervention: Walking exercise training (WET) for 30-60 minutes, 6 days a week for 12 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Walking exercise training (WET)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 27
Study: 12370850

Group type: EXPERIMENTAL
Intervention: LPL N291S gene variant
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: LPL D9N and S447X variants
Number of subjects: 195

Group type: COMPARATOR
Intervention: LPL447X allele
Number of subjects: 195

Group type: COMPARATOR
Intervention: IRS‐1, FABP‐2, and beta3‐AR gene variants
Number of subjects: 195
Study: 10428345

Group type: EXPERIMENTAL
Intervention: 50-g glucose challenge test
Number of subjects: 21
Study: 8784218

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 0
Study: 2099963

Group type: EXPERIMENTAL
Intervention: Defibrotide administered orally (400 mg b.i.d. for 15 days)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Defibrotide administered intramuscularly (200 mg b.i.d. for 15 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study: 317255

Group type: EXPERIMENTAL
Intervention: Clofibate (lipid-lowering substance) administered in a double-blind trial for an average of 5.3 years.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofibate (lipid-lowering substance)
Number of subjects: 0
Study: 28929830

Group type: EXPERIMENTAL
Intervention: Collaborative intervention process (six weekly sessions)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Collaborative intervention process (experimental group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 18
Study: 27939058

Group type: EXPERIMENTAL
Intervention: Cleaner burning biomass-fuelled cookstove intervention
Number of subjects: 10750

Group type: COMPARATOR
Intervention: Continuation of open fire cooking (Control)
Number of subjects: 10750
Study: 25630866

Group type: EXPERIMENTAL
Intervention: Listening to music during flexible cystoscopy
Number of subjects: 137

Group type: COMPARATOR
Intervention: Nonmusic group (control)
Number of subjects: 137
Study: 23760943

Group type: EXPERIMENTAL
Intervention: Nintendo Wii
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 21454834

Group type: EXPERIMENTAL
Intervention: Lithium disilicate glass-ceramic (LDGC) restorations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zirconium oxide (Y-TZP) restorations
Number of subjects: 0
Study: 19167953

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 99

Group type: COMPARATOR
Intervention: American Diabetes Association guidelines diet
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 99
Study: 17127227

Group type: EXPERIMENTAL
Intervention: 1 g t.i.d. of imipenem/cilastatin (group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 g t.i.d. of meropenem (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both carbapenems (imipenem and meropenem)
Number of subjects: 20
Study: 14985312

Group type: EXPERIMENTAL
Intervention: PKC412 150 mg/d
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: PKC412 100 mg/d
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: PKC412 100 mg/d and 150 mg/d
Number of subjects: 141

Group type: COMPARATOR
Intervention: PKC412 50 mg/d, 100 mg/d, 150 mg/d
Number of subjects: 141
Study: 11729699

Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 0
Study: 9924222

Group type: EXPERIMENTAL
Intervention: Bupivacaine up to 2 mg kg‐1, infiltrated around the inferior alveolar nerves bilaterally
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ketorolac 10 mg i.v. at the start of surgery
Number of subjects: 40
Study: 7822072

Group type: EXPERIMENTAL
Intervention: Subjects with previous severe unilateral ankle sprain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 0
Study: 2975610

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 13
Study: 31779923

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1767
Study: 30585472

Group type: EXPERIMENTAL
Intervention: Balance acupuncture plus motor relearning training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Motor relearning training
Number of subjects: 80
Study: 25130262

Group type: EXPERIMENTAL
Intervention: 1.4 g day(-1) omega-3 PUFAs plus cognitive behavioural case management
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo plus cognitive behavioural case management
Number of subjects: 400
Study: 25073573

Group type: EXPERIMENTAL
Intervention: Tanezumab 5mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tanezumab 10mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 0
Study: 22619101

Group type: EXPERIMENTAL
Intervention: Fascial relaxation along with conventional therapeutic exercises
Number of subjects: 35

Group type: COMPARATOR
Intervention: Classic kinesiotherapy (control group)
Number of subjects: 35
Study: 20511606

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17586713

Group type: EXPERIMENTAL
Intervention: Lingualized occlusal form
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Anatomic occlusal form
Number of subjects: 45

Group type: COMPARATOR
Intervention: Zero-degree occlusal form
Number of subjects: 45
Study: 15087034

Group type: EXPERIMENTAL
Intervention: HMVP regimen (hydroxycamptothecin 12 mg/m² d1-d5, mitomycin C 6 mg/m² d1, vindesine 2.5-3 mg/m² d1 and d8, cisplatin 50 mg/m² d2 and d3)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: MVP regimen (mitomycin C, vindesine, cisplatin same as HMVP)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: HVP regimen (hydroxycamptothecin, vindesine, cisplatin same as HMVP)
Number of subjects: 134

Group type: COMPARATOR
Intervention: All groups (HMVP, MVP, HVP)
Number of subjects: 134
Study: 10644862

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9058157

Group type: COMPARATOR
Intervention: Locoregional targeted chemotherapy only via an arterial catheter (Group A)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Combined locoregional immuno-chemotherapy via two arterial catheters (Group B)
Number of subjects: 193
Study: 7839878

Group type: EXPERIMENTAL
Intervention: Traditional anti-diabetic medicines (hospital-based trial for about 4 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Traditional treatment (ambulatory basis for up to 16 weeks)
Number of subjects: 18
Study: 2944006

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (250,000 U) followed by i.v. administration of streptokinase (500,000 U) in group 2.
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (250,000 U) in group 2.
Number of subjects: 533

Group type: COMPARATOR
Intervention: Conventional treatment in group 1.
Number of subjects: 533
Study: 3351336

Group type: EXPERIMENTAL
Intervention: Betamethasone Diproprionate in an optimized vehicle
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Clobetasol Proprionate ointment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: GCMS
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Urinary-free cortisol and 17-hydroxycortisol
Number of subjects: 38
Study: 29902649

Group type: EXPERIMENTAL
Intervention: Budesonide Oral Suspension (BOS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82